前往化源商城
入驻化源商城

140-79-4

140-79-4结构式
140-79-4结构式
  • 常用中文名:1,4-二亞硝哌
  • 常用英文名:N,N'-Dinitrosopiperazine
  • CAS号:140-79-4
  • 分子式:C4H8N4O2
  • 分子量:144.132
  • 相关类别: 信号通路 其他 其他
  • 发布时间:2018-05-08 08:00:00
  • 更新时间:2024-01-02 11:59:25
  • N,N'-Dinitrosopiperazine (1,4-Dinitrosopiperazine; DNP) 是一种致癌物 (carcinogen),特异性针对鼻咽癌,可促进鼻咽癌的转移。N,N'-Dinitrosopiperazine 通过蛋白磷酸化调节多种信号通路,包括 LYRIC,在丝氨酸 568 位。

化源商城直购

中文名 1,4-二亞硝哌
英文名 1,4-Dinitrosopiperazine
英文别名 EINECS 205-434-6
NN'-Dinitrosopiperazine
Piperazine, 1,4-dinitroso-
1,4-Dinitrosopiperazine
描述 N,N'-Dinitrosopiperazine (1,4-Dinitrosopiperazine; DNP) 是一种致癌物 (carcinogen),特异性针对鼻咽癌,可促进鼻咽癌的转移。N,N'-Dinitrosopiperazine 通过蛋白磷酸化调节多种信号通路,包括 LYRIC,在丝氨酸 568 位。
相关类别
体外研究 N、 N'-二硝基哌嗪(0.5-100μM;48h)对标记的6-10B细胞无抑制作用,在0.5-8μM浓度范围内,DNP处理对LDH活性无明显影响。然而,从10μM的浓度来看,它具有细胞毒性[1]。N、 N'-二硝基哌嗪(2-8μM;24小时)诱导6-10B细胞侵袭和运动,呈剂量依赖性。在6μM时,与对照组相比,DNP增加了421.7%的细胞侵袭力和328.2%的细胞运动性[1]。N、 N'-二硝基哌嗪(6μM;24小时)增加CNE1细胞磷酸化LYRIC s568的表达和LYRIC的表达[1]。细胞活力测定[1]细胞系:标记的6-10B细胞浓度:0.5,1,2,4,6,8,10,20,40,80,或100μM孵育时间:48小时结果:在0-8μM浓度下没有抑制作用[1]细胞系:鼻咽癌细胞系CNE1浓度:6μM孵育时间:24小时结果:磷酸化抒情s568和LYRIC表达增加。
体内研究 N、 N'-二硝基哌嗪(尾静脉注射;40mg/kg;30天)抑制细胞运动和侵袭,促进鼻咽癌的体内转移。从IHC的结果来看,DNP治疗小鼠的转移瘤中磷酸化表达高于未经处理的对照小鼠[1]。动物模型:BABL/c裸鼠,分别注射6-10B细胞悬液(1 × 104细胞)加或不加DNP(40mg/kg)[1]剂量:40mg/kg给药:尾静脉注射;30天结果:体内诱导丝氨酸568处的抒情磷酸化与鼻咽癌转移有关。
参考文献

[1]. Damao Huang, et al. Identification of Novel Signaling Components in N,N'-dinitrosopiperazine-mediated Metastasis of Nasopharyngeal Carcinoma by Quantitative Phosphoproteomics. BMC Cancer. 2014 Apr 5;14:243.

密度 1.5±0.1 g/cm3
沸点 406.1±38.0 °C at 760 mmHg
分子式 C4H8N4O2
分子量 144.132
闪点 199.4±26.8 °C
精确质量 144.064728
PSA 65.34000
LogP -0.88
蒸汽压 0.0±0.9 mmHg at 25°C
折射率 1.648
计算化学

1.疏水参数计算参考值(XlogP):无

2.氢键供体数量:0

3.氢键受体数量:6

4.可旋转化学键数量:0

5.互变异构体数量:无

6.拓扑分子极性表面积65.3

7.重原子数量:10

8.表面电荷:0

9.复杂度:115

10.同位素原子数量:0

11.确定原子立构中心数量:0

12.不确定原子立构中心数量:0

13.确定化学键立构中心数量:0

14.不确定化学键立构中心数量:0

15.共价键单元数量:1

CHEMICAL IDENTIFICATION

RTECS NUMBER :
TL6300000
CHEMICAL NAME :
Piperazine, 1,4-dinitroso-
CAS REGISTRY NUMBER :
140-79-4
BEILSTEIN REFERENCE NO. :
0135106
LAST UPDATED :
199701
DATA ITEMS CITED :
38
MOLECULAR FORMULA :
C4-H8-N4-O2
MOLECULAR WEIGHT :
144.16
WISWESSER LINE NOTATION :
T6N DNTJ ANO DNO

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
160 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
160 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
100 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1040 mg/kg/1Y-I
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Gastrointestinal - tumors Liver - tumors
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1070 mg/kg/53W-I
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Gastrointestinal - tumors Liver - tumors
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
140 mg/kg female 15-21 day(s) after conception
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Reproductive - Tumorigenic effects - transplacental tumorigenesis Blood - leukemia
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1568 mg/kg/28W-C
TOXIC EFFECTS :
Tumorigenic - neoplastic by RTECS criteria Lungs, Thorax, or Respiration - tumors
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
720 mg/kg/72W-I
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Lungs, Thorax, or Respiration - tumors Liver - tumors
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1800 mg/kg/64W-C
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Gastrointestinal - tumors
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1100 mg/kg/110W-I
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Gastrointestinal - tumors
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
2250 mg/kg/50W-I
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Sense Organs and Special Senses (Olfaction) - tumors Liver - tumors
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
7300 mg/kg/52W-C
TOXIC EFFECTS :
Tumorigenic - neoplastic by RTECS criteria Lungs, Thorax, or Respiration - tumors
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
560 mg/kg/10W-C
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Sense Organs and Special Senses (Olfaction) - tumors
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
300 mg/kg
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Skin and Appendages - tumors
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1086 mg/kg/69W-I
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Brain and Coverings - tumors Gastrointestinal - tumors
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
5280 mg/kg/44W-I
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Lungs, Thorax, or Respiration - tumors Liver - tumors
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1120 mg/kg/20W-C
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Sense Organs and Special Senses (Olfaction) - tumors
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1680 mg/kg/30W-C
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Sense Organs and Special Senses (Olfaction) - tumors
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
140 mg/kg
SEX/DURATION :
female 15-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - live birth index (measured after birth)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
400 mg/kg
SEX/DURATION :
lactating female 20 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
TYPE OF TEST :
Specific locus test
TYPE OF TEST :
DNA damage
TYPE OF TEST :
Unscheduled DNA synthesis
TYPE OF TEST :
DNA inhibition
TYPE OF TEST :
DNA inhibition
TYPE OF TEST :
Cytogenetic analysis

MUTATION DATA

TYPE OF TEST :
Host-mediated assay
TEST SYSTEM :
Rodent - mouse Bacteria - Salmonella typhimurium
DOSE/DURATION :
10 mg/kg
REFERENCE :
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 37,4572,1977

海关编码 2933599090
海关编码 2933599090
中文概述 2933599090. 其他结构上有嘧啶环的化合物(包括其他结构上有哌嗪环的化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素 品名, 成分含量, 用途, 乌洛托品请注明外观, 6-己内酰胺请注明外观, 签约日期
Summary 2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%